Intrathecal corticosteroids might slow Alzheimer’s disease progression

Intrathecal corticosteroids might slow Alzheimer’s disease progression

Joseph Martin Alisky1,21Marshfield Clinic Research Foundation; 2Marshfield Clinic-Thorp Center, Marshfield, Wisconsin, USAAbstract: Anti-inflammatory drugs for treatment and prevention of Alzheimer’s disease have to date proved disappointing, including a large study of low-dose prednis...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Joseph Martin Alisky
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/a7bb9ad46b8e43bebd7a081728de5468
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a7bb9ad46b8e43bebd7a081728de5468
record_format dspace
spelling oai:doaj.org-article:a7bb9ad46b8e43bebd7a081728de54682021-12-02T07:10:46ZIntrathecal corticosteroids might slow Alzheimer’s disease progression1176-63281178-2021https://doaj.org/article/a7bb9ad46b8e43bebd7a081728de54682008-09-01T00:00:00Zhttp://www.dovepress.com/intrathecal-corticosteroids-might-slow-alzheimerrsquos-disease-progres-a2154https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Joseph Martin Alisky1,21Marshfield Clinic Research Foundation; 2Marshfield Clinic-Thorp Center, Marshfield, Wisconsin, USAAbstract: Anti-inflammatory drugs for treatment and prevention of Alzheimer’s disease have to date proved disappointing, including a large study of low-dose prednisone, but higher dose steroids significantly reduced amyloid secretion in a small series of nondemented patients. In addition, there is a case report of a patient with amyloid angiopathy who had complete remission from two doses of dexamethasone, and very high dose steroids are already used for systemic amyloidosis. This paper presents the hypothesis that pulse-dosed intrathecal methylprednisolone or dexamethasone will produce detectable slowing of Alzheimer’s progression, additive to that obtained with cholinesterase inhibitors and memantine. A protocol based on treatment regimens for multiple sclerosis and central nervous system lupus is outlined, to serve as a basis for formulating clinical trials. Ultimately intrathecal corticosteroids might become part of a multi-agent regimen for Alzheimer’s disease and also have application for other neurodegenerative disorders.Keywords: Alzheimer’s disease, inflammation, corticosteroids Joseph Martin AliskyDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 5, Pp 831-833 (2008)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Joseph Martin Alisky
Intrathecal corticosteroids might slow Alzheimer’s disease progression
description Joseph Martin Alisky1,21Marshfield Clinic Research Foundation; 2Marshfield Clinic-Thorp Center, Marshfield, Wisconsin, USAAbstract: Anti-inflammatory drugs for treatment and prevention of Alzheimer’s disease have to date proved disappointing, including a large study of low-dose prednisone, but higher dose steroids significantly reduced amyloid secretion in a small series of nondemented patients. In addition, there is a case report of a patient with amyloid angiopathy who had complete remission from two doses of dexamethasone, and very high dose steroids are already used for systemic amyloidosis. This paper presents the hypothesis that pulse-dosed intrathecal methylprednisolone or dexamethasone will produce detectable slowing of Alzheimer’s progression, additive to that obtained with cholinesterase inhibitors and memantine. A protocol based on treatment regimens for multiple sclerosis and central nervous system lupus is outlined, to serve as a basis for formulating clinical trials. Ultimately intrathecal corticosteroids might become part of a multi-agent regimen for Alzheimer’s disease and also have application for other neurodegenerative disorders.Keywords: Alzheimer’s disease, inflammation, corticosteroids
format article
author Joseph Martin Alisky
author_facet Joseph Martin Alisky
author_sort Joseph Martin Alisky
title Intrathecal corticosteroids might slow Alzheimer’s disease progression
title_short Intrathecal corticosteroids might slow Alzheimer’s disease progression
title_full Intrathecal corticosteroids might slow Alzheimer’s disease progression
title_fullStr Intrathecal corticosteroids might slow Alzheimer’s disease progression
title_full_unstemmed Intrathecal corticosteroids might slow Alzheimer’s disease progression
title_sort intrathecal corticosteroids might slow alzheimer’s disease progression
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/a7bb9ad46b8e43bebd7a081728de5468
work_keys_str_mv AT josephmartinalisky intrathecalcorticosteroidsmightslowalzheimeramprsquosdiseaseprogression
_version_ 1718399593920593920

Ejemplares similares